C07K 14/03
Herpetoviridae
Official title: Herpetoviridae, e.g. pseudorabies virus
C07K14/03 (Herpetoviridae) appears on 128 US grants and 193 published applications in this corpus.
Search patents in C07K- Granted patents
- 128
- Published applications
- 193
- Assignees
- 111
- Inventors
- 355
- Latest grant
- 3 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2004 | 0 | 2 |
| 2005 | 0 | 2 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 1 | 1 |
| 2009 | 1 | 4 |
| 2010 | 0 | 1 |
| 2011 | 2 | 1 |
| 2012 | 3 | 5 |
| 2013 | 7 | 16 |
| 2014 | 7 | 6 |
| 2015 | 3 | 7 |
| 2016 | 7 | 9 |
| 2017 | 4 | 6 |
| 2018 | 5 | 9 |
| 2019 | 11 | 18 |
| 2020 | 10 | 14 |
| 2021 | 10 | 29 |
| 2022 | 12 | 15 |
| 2023 | 14 | 9 |
| 2024 | 21 | 20 |
| 2025 | 8 | 12 |
| 2026 | 2 | 7 |
By publication year. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Epstein-BARR virus nucleic acid constructs and vaccines made therefrom, and methods of using same3 Mar 2026US 12,564,628 B2The Wistar Institute of Anatomy and Biology
- Therapeutic nanoconjugates comprising Stefin A and uses thereof3 Feb 2026US 12,540,172 B2Consorcio Centro de Investigación Biomédica en Red, M. P.
- Human cytomegalovirus gB polypeptide21 Oct 2025US 12,447,207 B2Pfizer Inc.
- Antibodies and methods for the diagnosis and treatment of Epstein Barr virus infection9 Sep 2025US 12,410,240 B2The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
- Modified cytomegalovirus proteins and stabilized complexes12 Aug 2025US 12,384,819 B2Glaxosmithkline Biologicals SA
- Modified cytomegalovirus proteins and stabilized complexes27 Aug 2026US 2026/0250330 A1Glaxosmithkline Biologicals SA
- Hsv gene expression vector and bxb1 integrase-mediated recombination system for high-throughput cloning27 Aug 2026US 2026/0250643 A1Albert Einstein College of Medicine
- Human cytomegalovirus gb polypeptide20 Aug 2026US 2026/0240988 A1Pfizer Inc.
- Fusion protein of ge and gi of varicella-zoster virus and use6 Aug 2026US 2026/0224694 A1
- Nucleic Acid Vaccines for Varicella-Zoster Virus (VZV)6 Aug 2026US 2026/0224695 A1Everest Medicines (Singapore) Pte. Ltd.
Most cited
By later US patents
- Nucleotide-specific recognition sequences for designer TAL effectors84US 8,450,107 B1Massachusetts Institute of Technology · 2013
- Nucleotide-specific recognition sequences for designer TAL effectors84US 8,614,092 B2Massachusetts Institute of Technology · 2013
- Nucleotide-specific recognition sequences for designer TAL effectors76US 8,507,272 B2Massachusetts Institute of Technology · 2013
- Nucleotide-specific recognition sequences for designer TAL effectors67US 8,481,309 B2Massachusetts Institute of Technology · 2013
- FGF21 mutant fusion polypeptides and uses thereof59US 8,642,546 B2Amgen Inc. · 2014